PharmacyCodes



Ergoton-a [As Succinate] en es it fr

Ergoton-a [As Succinate] Brand names, Ergoton-a [As Succinate] Analogs

Ergoton-a [As Succinate] Brand Names Mixture

  • Bellergal Spacetabs (Belladonna + Ergotamine Tartrate + Phenobarbital)
  • Bellergal Tab (Belladonna + Ergotamine (Ergotamine Tartrate) + Phenobarbital)
  • Cafergot Pb Sup (Belladonna + Caffeine + Ergotamine (Ergotamine Tartrate) + Pentobarbital)
  • Cafergot Pb Tab (Belladonna + Caffeine + Ergotamine (Ergotamine Tartrate) + Pentobarbital Sodium)
  • Cafergot Sup (Caffeine + Ergotamine Tartrate)
  • Cafergot Tab (Caffeine + Ergotamine Tartrate)
  • Ergodryl Cap (Caffeine Citrate + Diphenhydramine Hydrochloride + Ergotamine Tartrate)
  • Gravergol Capsules (Caffeine + Dimenhydrinate + Ergotamine Tartrate)
  • Megral Tabs (Caffeine + Cyclizine Hydrochloride + Ergotamine Tartrate)
  • Wigraine Suppositories (Belladonna + Caffeine + Ergotamine Tartrate)
  • Wigraine Tab (Belladonna + Caffeine + Ergotamine Tartrate)

Ergoton-a [As Succinate] Chemical_Formula

C33H35N5O5

Ergoton-a [As Succinate] RX_link

http://www.rxlist.com/cgi/generic2/ergotamine.htm

Ergoton-a [As Succinate] fda sheet

http://www.fda.gov/cder/foi/label/2002/05929s32s33lbl.pdf

Ergoton-a [As Succinate] msds (material safety sheet)

Ergoton-a_[As_Succinate] MSDS

Ergoton-a [As Succinate] Synthesis Reference

No information avaliable

Ergoton-a [As Succinate] Molecular Weight

581.662 g/mol

Ergoton-a [As Succinate] Melting Point

213.5 oC

Ergoton-a [As Succinate] H2O Solubility

Slight

Ergoton-a [As Succinate] State

Solid

Ergoton-a [As Succinate] LogP

2.53

Ergoton-a [As Succinate] Dosage Forms

Tablet

Ergoton-a [As Succinate] Indication

For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".

Ergoton-a [As Succinate] Pharmacology

Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow.

Ergoton-a [As Succinate] Absorption

No information avaliable

Ergoton-a [As Succinate] side effects and Toxicity

Signs of overexposure include irritation, nausea, vomiting, headache, diarrhea, thirst, coldness of skin, pruritus, weak pulse, numbness, tingling of extremities, and confusion.

Ergoton-a [As Succinate] Patient Information

No information avaliable

Ergoton-a [As Succinate] Organisms Affected

Humans and other mammals